TREEFROG THERAPEUTICS

Cell therapies derived from induced pluripotent stem cells (iPSCs) represent one of the most promising frontiers in regenerative medicine: in theory, they make it possible to produce any type of therapeutic cell from reprogrammed patient cells, opening the door to personalised treatments for diseases that are currently incurable. In practice, the path from promise to clinic is blocked by a fundamental problem — the production of these cells is expensive, difficult to scale, and often unstable. TreeFrog Therapeutics, a French biotech company, has tackled this bottleneck by developing a proprietary bioproduction platform designed to make iPSC-derived therapies safer, more efficient, and more economically accessible. The approach is that of process engineering applied to biology: building cell culture systems that guarantee quality and reproducibility at industrial scale, reducing unit costs enough to make these therapies economically sustainable for healthcare systems. TreeFrog's target is not the end patient but the biopharma companies, research centres, and clinical organisations that develop or scale cell therapies — a B2B positioning where value is measured in the ability to accelerate partners' therapeutic programmes. The cell therapy market is expanding rapidly, but the production cost barrier has until now limited commercialisation. TreeFrog positions itself as the infrastructure that removes this barrier, turning frontier biology into accessible medicine.